COMP <GO>
PGNY vs VMD // EV/EBITDA & P/E VALUATION
Progyny Inc. (NASDAQ) VS. Viemed Healthcare Inc. (NASDAQ) • 15-METRIC TALLY: PGNY 5
— VMD 7
▲ EV/EBITDA & P/E VALUATION LEADER: VMD
LAST: $28.40 (+1.90%) • MKT CAP: $2.18B
valuation
20.5x
LAST: $9.95 (-0.40%) • MKT CAP: $379.0M
valuation
6.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PGNY VS. VMD)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | PGNY | VMD | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 23.60% | 57.50% | -33.90 | VMD | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 16.70% | 13.00% | +3.70 | PGNY | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 20.5x | 6.6x | +13.90 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 8.80% | 3.15% | +5.65 | PGNY | /fcf-yield <GO> |
| Operating Margin | 6.60% | 8.50% | -1.90 | VMD | /operating-margins <GO> |
| Net Profit Margin | 4.50% | 5.70% | -1.20 | VMD | /net-margins <GO> |
| Revenue Growth (YoY) | 10.40% | 20.50% | -10.10 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.84 | 6.59 | +2.25 | PGNY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 9/9 | -2.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 62.0 | 53.1 | +8.91 | PGNY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 34.6x | 20.7x | +13.90 | VMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.18B | $379.0M | $1.80B | PGNY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | PGNY REV | VMD REV | PGNY GROSS % | VMD GROSS % | PGNY FCF | VMD FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.29B | $270.3M | 23.6% | 57.5% | $191.8M | $11.9M |
| FY 2024 | $1.17B | $224.3M | 21.7% | 59.4% | $173.7M | $1.3M |
| FY 2023 | $1.09B | $183.0M | — | — | $188.8M | $45.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PGNY // BETA —
VMD // BETA —